Pascal Soriot, AstraZeneca CEO (David Zorrakino/Europa Press via AP)

As­traZeneca joins Boehringer In­gel­heim in cap­ping out-of-pock­et in­haler costs at $35

Just as in­sulin man­u­fac­tur­ers were pres­sured in­to cap­ping month­ly out-of-pock­et costs, in­haler man­u­fac­tur­ers are feel­ing the same heat. As­traZeneca on Mon­day joined with Boehringer In­gel­heim …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.